DTIL Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (19 Apr 2024 @ 16:00):

Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing and ex vivo allogeneic CAR T therapies in the United States...

Stats
Today's Volume	170 483
Average Volume	127 877
Market Cap	67.36M
EPS	$0 ( 2024-03-27 )
Next earnings date	( $-0.450 ) 2024-05-14
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.0300
ATR14	$0.0750 (0.77%)

Insider Trading

Date	Person	Action	Amount	type
2024-01-20	Kelly John Alexander	Buy	116 690	Common Stock
2024-01-20	Kelly John Alexander	Sell	116 690	Restricted Stock Units
2024-01-20	Amoroso Michael	Sell	266 720	Restricted Stock Units
2024-01-20	Amoroso Michael	Buy	266 720	Common Stock
2024-01-22	Amoroso Michael	Sell	137 390	Common Stock

INSIDER POWER
32.41
Last 99 transactions
Buy: 5 951 579 \| Sell: 2 142 978

Volume Correlation

Long: 0.01 (neutral)

Short: -0.06 (neutral)

Signal:(47.109) Neutral

Precision BioSciences Inc Correlation

10 Most Positive Correlations
RMRM	0.953
APOP	0.932
PRPO	0.929
SISI	0.913
XNCR	0.909
CTRM	0.909
OXSQ	0.908
SPTN	0.907
TIL	0.907
AXLA	0.906

10 Most Negative Correlations
MMAC	-0.93
OBT	-0.926
ZGNX	-0.918
MPRA	-0.903
ADMS	-0.901
ARNA	-0.898
NETE	-0.898
NCAC	-0.896
NSIT	-0.895
PLPC	-0.894

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Precision BioSciences Inc Correlation - Currency/Commodity

-0.59
( weak negative )

-0.34
( neutral )

0.00
( neutral )

-0.56
( weak negative )

0.42
( neutral )

0.06
( neutral )

Precision BioSciences Inc Financials

Annual	2023
Revenue:	$48.73M
Gross Profit:	$40.47M (83.06 %)
EPS:	$-18.16

Q4	2023
Revenue:	$7.04M
Gross Profit:	$5.48M (77.89 %)
EPS:	$-4.06

Q3	2023
Revenue:	$13.12M
Gross Profit:	$11.08M (84.48 %)
EPS:	$-2.10

Q2	2023
Revenue:	$19.79M
Gross Profit:	$17.40M (87.95 %)
EPS:	$-3.13

Financial Reports:

No articles found.

Precision BioSciences Inc

Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing and ex vivo allogeneic CAR T therapies in the United States. It offers ARCUS, a genome editing platform to cure genetic disorders. The company also provides Ex vivo Allogeneic CAR T Immunotherapy, a form of immunotherapy in which T cell, a specific type of immune cell is genetically engineered to recognize and kill cancer cells; PBCAR0191, which is in Phase 1/2a clinical trial in adult patients with R/R NHL or R/R B-cell precursor acute lymphoblastic leukemia, or B-ALL; PBCAR19B, an anti-CD19 CAR T candidate built on the stealth cell platform utilizing a single-step gene edit to minimize the risk of chromosome abnormalities; and PBCAR269A, an investigational allogeneic CAR T immunotherapy targeting BCMA for the treatment of R/R multiple myeloma. The company has development and commercial license agreement with Les Laboratoires Servier to develop allogeneic chimeric antigen receptor T cell therapies for antigen targets, hematological cancer targets beyond CD19, and solid tumor targets; Tiziana Life Sciences to evaluate foralumab, a fully human anti-CD3 monoclonal antibody as a lymphodepleting agent for the potential treatment of cancers; and iECURE, Inc. to develop ARCUS-based gene editing therapies. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.